Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Summary

This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer. Chemotherapy drugs, such as fludarabine, thiotepa, etoposide, melphalan, and rabbit anti-thymocyte globulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.

Conditions

• Anaplastic Ependymoma
• Atypical Teratoid/Rhabdoid Tumor
• Central Nervous System Germ Cell Tumor
• Choroid Plexus Carcinoma
• Intracranial Myeloid Sarcoma
• Malignant Brain Neoplasm
• Malignant Glioma
• Medulloblastoma
• Primitive Neuroectodermal Tumor
• Recurrent Anaplastic Ependymoma
• Recurrent Atypical Teratoid/Rhabdoid Tumor
• Recurrent Malignant Brain Neoplasm
• Recurrent Malignant Glioma
• Recurrent Medulloblastoma
• Recurrent Primitive Neuroectodermal Tumor

Interventions

DRUG

Etoposide

Given IV

DRUG

Fludarabine Phosphate

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo HCT

BIOLOGICAL

Lapine T-Lymphocyte Immune Globulin

Given IV

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given PO or IV

DRUG

Tacrolimus

Given IV

DRUG

Thiotepa

Given IV

Sponsors & Collaborators

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Kris M Mahadeo, MD · M.D. Anderson Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Max Age

25 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-01-14

Primary Completion

2022-12-20

Completion

2022-12-20

FDA Drug

Yes